Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk

Novo Nordisk (NVO) announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion for Wegovy (semaglutide 2.4 mg) to reduce the risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack or stroke in adults with either overweight or obesity and established cardiovascular disease.Wegovy, a GLP-1 agonist, is Novo Nordisk’s blockbuster chronic weight management injection approved for adults with obesity or overweight. Th ...